Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 17/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309245 | 0.87 | HDAC1 (0.68) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4321246 | 0.87 | HDAC1 (0.68) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4309593 | 0.87 | HDAC1 (0.68) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4318134 | 0.86 | HDAC1 (0.65) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4305941 | 0.84 | HDAC1 (0.66) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4309231 | 0.84 | HDAC1 (0.69) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4580132 | 0.83 | MCHR1 (0.74) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4580136 | 0.83 | MCHR1 (0.74) | KCNH2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4578742 | 0.81 | HDAC1 (0.63) | KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL4580616 | 0.81 | HDAC1 (0.63) | KCNH2HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | claimed |
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | MERCK SHARP & DOHME CORP. | 2009-01-08 | — | — | US | disclosed |
| EP-1976511-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007087129-A2 | FLUORINATED ARYLAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012075-A1 | Fluorinated Arylamide Derivatives | HDAC5, AADAC, HDAC6 | KCNH2 3254/4885HDAC1 4/4885HDAC2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.